Skip to search formSkip to main contentSkip to account menu

nepicastat

Known as: 5-aminomethyl-1-(5,7-difluoro-1,2,3,4-tetrahydronaphth-2-yl)-1,3-dihydroimidazole-2-thione 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

ImidazolesThiones
Nepicastat Hydrochloride

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Lack of zinc finger protein 521 upregulates dopamine β-hydroxylase expression in the mouse brain, leading to abnormal behavior.
2016
2016
Studio dell’Effetto dell’Inibitore Selettivo della Dopamina β-Idrossilasi, Nepicastat, su Modelli Animali di “Alcohol Addiction” e “Chocolate Addiction”
Background: Nepicastat is a selective dopamine β-hydroxylase (DBH) inhibitor that has been found to suppress the reinstatement… 
2015
2015
Characterization of the interaction of the novel antihypertensive etamicastat with human dopamine-β-hydroxylase: comparison with nepicastat.
2014
2014
The dopamine beta‐hydroxylase inhibitor nepicastat increases dopamine release and potentiates psychostimulant‐induced dopamine release in the prefrontal cortex
The dopamine‐beta‐hydroxylase inhibitor nepicastat has been shown to reproduce disulfiram ability to suppress the reinstatement… 
2014
2014
The dopamine β-hydroxylase inhibitor, nepicastat, reduces different alcohol-related behaviors in rats.
BACKGROUND Recent experimental data indicate that treatment with the selective dopamine β-hydroxylase inhibitor, nepicastat… 
2014
2014
Examining the utility of using genotype and functional biology in a clinical pharmacology trial: pilot testing dopamine β-hydroxylase, norepinephrine, and post-traumatic stress disorder.
One of the major clinical problems faced in treating posttraumatic stress disorder (PTSD) is that no single treatment is… 
2011
2011
Structural Insight of Dopamine β-Hydroxylase, a Drug Target for Complex Traits, and Functional Significance of Exonic Single Nucleotide Polymorphisms
Background Human dopamine β-hydroxylase (DBH) is an important therapeutic target for complex traits. Several single nucleotide… 
Review
1999
Review
1999
Dopamine-beta-hydroxylase inhibition: a novel sympatho-modulatory approach for the treatment of congestive heart failure.
Pre-clinical and clinical studies suggest that chronic sympathetic activation in congestive heart failure (CHF) is a maladaptive… 
1998
1998
Dopamine Beta-Hydroxylase Inhibition: A Potential Therapy for the Treatment of Congestive Heart Failure
Chronic sympathetic activation in congestive heart failure (CHF) is considered a maladaptive response. Consequently, therapeutic… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)